MosaMeat BV closes US$85m Series B financing
Cultured meat producer MosaMeat BV has announced the third and final closing of its Series B round raising US$85m.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2170 entries already.
Cultured meat producer MosaMeat BV has announced the third and final closing of its Series B round raising US$85m.
DASbox® Mini Bioreactor System: In the Quality by Design (QbD) and Process Analytical Technology (PAT) era, the generation and validation of a large amount of data have become standard. Parallel bioreactor control systems offer the possibility to test and optimize different process parameters at the same time, thus saving time and resources.
Austrian researchers have found that a lack of activation of the NK receptor is highly associated with severe COVID-19 disease courses.
Swiss cancer vaccine specialist MaxiVAX SA has hired Minaris Regenerative Medicine GmbH to produce its cell therapy MVX-ONCO-2.
Pfizer Inc. and BioNTech SE have signed an agreement with the European Commission (EC) to supply an additional 200 million doses of BNT162b2 to the EU.
A resesarch team headed by HepaRegeneriX Board Member Lars Zender has presented a new approach to treat hepatocellular carcinoma (HCC) by disturbing the lipid metabolism of tumour cells.
Cell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies.
Cellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries.
CDMO Rentschler Biopharma will establish a Center of Excellence for cell and gene therapy through a new UK subsidiary Rentschler ATMP Ltd.

